David Alain Wohl, M.D.
David Alain Wohl, M.D., is a professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC). He is site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AIDS Education and Training Center (AETC), and co-director of HIV services for the North Carolina state prison system. In 2014, he became co-director of the UNC-Duke Clinical RM Ebola Response Consortium.
Dr. Wohl's research aims to optimize the treatment of HIV, including identifying the most effective therapeutic approaches and minimizing the adverse effects of therapy. He is also active in investigations focused on populations vulnerable to HIV, such as the incarcerated. He is active within the U.S. AIDS Clinical Trials Group and HIV Prevention Trials Network and served two terms as a member of the U.S. Department of Health and Human Services Antiretroviral Guidelines Panel.
As part of the response to the 2013-2016 Ebola outbreak in West Africa, Dr. Wohl led UNC clinical research efforts to test interventions for Ebola Virus Disease in Liberia and now directs a clinical cohort of Ebola survivors.
In addition to his research and administrative activities, Dr. Wohl maintains a large HIV continuity clinic at UNC.
Dr. Wohl has attended advisory boards for Abbott Laboratories, Tibotec, Janssen Pharmaceuticals, ViiV Healthcare, and Gilead Sciences. In addition, his university has received support for his research from Gilead Sciences and ViiV Healthcare. These disclosures were last updated on November 17, 2017.
Latest by David Alain Wohl, M.D.
Analysis from David Alain Wohl, M.D., on new research in on HIV prevention, especially in areas that will expand and transform PrEP options.
David Alain Wohl, M.D., shares his thoughts on broadly neutralizing antibodies for COVID-19—and the extent to which we can hope to see similar developments in HIV.
David Alain Wohl, M.D., on new findings from CROI 2021 that help us better understand the connections between sleep, diet, and quality of life among people living with HIV.
David Alain Wohl, M.D., talks through new data regarding long-acting antiretroviral therapy for HIV—and touches on the uncertainties clinicians face in incorporating this new treatment method into their practice.
Hypertension Control Emerges as Key Concern in Examination of HIV, Aging, and Cardiovascular Disease
David Alain Wohl, M.D., talks through new data presented at CROI 2021 that further our understanding of the interplay between HIV and comorbidities we often associate with aging, particularly those related to cardiovascular disease.
David Alain Wohl, M.D., analyzes updated data regarding the intersection of HIV and COVID-19, with a particular focus on SARS-CoV-2 susceptibility and disease severity.
In this exclusive series of articles, David Alain Wohl, M.D., calls attention to 10 developments that have tremendous short-term implications for our day-to-day efforts to improve HIV prevention, treatment, patient care, and policy in the U.S., and analyzes each development with his trademark wit and clinical savvy.
While we remain uncertain about the precise level of interaction (if any) between HIV and SARS-CoV-2 on a pathophysiological level, the pandemic’s disruption of HIV care is irrefutable.
PrEP for HIV is a pill. It has always been a pill. But it will not always be a pill, thanks to two major trials evaluating cabotegravir, an integrase inhibitor formulated for intramuscular injection, as PrEP.
An important new analysis describes a key barrier to PrEP in the U.S., one that is almost sinister in its application predominantly in southern states.